10-Q: Autolus Q3 2025: AUCATZYL Sales Drive Revenue Growth

Autolus Therapeutics reports significant product revenue from AUCATZYL in Q3 2025, alongside ongoing clinical advancements and strategic market expansion efforts.

Summary

• Net loss for the three months ended September 30, 2025, was $79.1 million, compared to $82.1 million for the same period in 2024.
• Net loss for the nine months ended September 30, 2025, was $197.2 million, compared to $193.1 million for the same period in 2024.
• Product revenue, net, for the three months ended September 30, 2025, was $21.1 million, with total product revenue, net, of $51.0 million for the nine months ended September 30, 2025, marking the first commercial sales of AUCATZYL in the United States.
• Cash and cash equivalents stood at $86.1 million, and marketable securities at $281.3 million, as of September 30, 2025.
• The accumulated deficit reached $1,296.4 million as of September 30, 2025.
• 60 cancer treatment centers are fully activated in the United States for AUCATZYL, achieving the year-end target.
• Patient access to AUCATZYL in the United States covers greater than 90% of total medical lives.
• The European Commission granted marketing authorization for AUCATZYL in July 2025, but launch in Germany is on hold, and no EU sales are anticipated in 2025 and 2026.
• Obe-cel received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for pediatric relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL) in October 2025.
• Preliminary data from the Phase 1 CARLYSLE clinical trial for obe-cel in severe refractory systemic lupus erythematosus (srSLE) showed 83% achievement of definition of remission in SLE (DORIS) and 50% complete renal response.

Sentiment

Score: 4

Explanation: While the company achieved its first product revenue and made clinical progress, significant operating losses, increased cash burn, and delays/challenges in EU commercialization and orphan drug status temper the positive developments. The explicit need for additional capital contributes to a neutral to slightly negative sentiment.

Positives

• Generated first product revenue from AUCATZYL sales in the United States, totaling $21.1 million in Q3 2025 and $51.0 million for the nine months ended September 30, 2025.
• Successfully activated 60 cancer treatment centers in the United States for AUCATZYL, meeting the target prior to year-end.
• Secured patient access to AUCATZYL for over 90% of total United States medical lives.
• Received conditional marketing authorization for AUCATZYL in the United Kingdom from the MHRA in April 2025.
• Granted marketing authorization for AUCATZYL in adult patients (age 26 and older) with r/r B-ALL by the European Commission in July 2025.
• Obe-cel received RMAT designation from the FDA for pediatric r/r B-ALL, which is expected to accelerate development and regulatory review.
• Positive preliminary efficacy and safety data from the Phase 1 CARLYSLE clinical trial for obe-cel in lupus nephritis, showing high response rates and no high-grade cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS).
• Advanced obe-cel into initial clinical development for progressive multiple sclerosis (MS) with the first patient dosed in the Phase 1 BOBCAT trial in October 2025.
• Moderna initiated a Phase 1/2 study of mRNA-2808, an investigational mRNA-based T-cell engager, utilizing Autolus' proprietary binder, demonstrating successful collaboration.
• Foreign exchange losses decreased significantly in Q3 2025 compared to Q3 2024, and the nine-month period saw a gain compared to a loss in the prior year.

Negatives

• Continued to incur significant operating losses, with a net loss of $197.2 million for the nine months ended September 30, 2025, and an accumulated deficit of $1,296.4 million.
• Net cash used in operating activities increased to $216.2 million for the nine months ended September 30, 2025, from $168.3 million in the prior year period.
• Cash and cash equivalents decreased significantly to $86.1 million as of September 30, 2025, from $227.4 million as of December 31, 2024.
• Marketable securities also decreased to $281.3 million as of September 30, 2025, from $360.6 million as of December 31, 2024.
• Cost of sales ($28.6 million in Q3 2025) exceeded product revenue ($21.1 million) in the quarter, indicating negative gross margin for the newly launched product.
• Launch of AUCATZYL in Germany is on hold, and no EU sales are anticipated in 2025 and 2026, despite receiving marketing authorization.
• Voluntarily withdrew obe-cel from the EU register of orphan medicinal products due to difficulty achieving a commercially viable price in the absence of orphan drug designation.
• Interest income decreased to $15.8 million for the nine months ended September 30, 2025, from $24.9 million in the prior year, primarily due to lower aggregate balances and yield on cash and marketable securities.
• Income tax expenses increased to $3.2 million for the nine months ended September 30, 2025, from less than $0.1 million in the prior year, due to increased taxable income from US product revenue.

Risks

• May not obtain or maintain the benefits associated with orphan drug designation, including market exclusivity or favorable pricing, as evidenced by the voluntary withdrawal of obe-cel from the EU orphan medicinal products register.
• Products and product candidates are subject to government price controls in certain jurisdictions, which may affect the ability to receive adequate coverage and reimbursement for AUCATZYL, potentially impacting profitability.
• Policies from the current U.S. presidential administration (e.g., Most-Favored Nation pricing, direct-to-patient discounts, tariffs) could significantly reduce U.S. drug prices, increase operational costs, and compliance risks.
• The CMS policy to split the therapeutic dose of AUCATZYL into two administrations for coding and billing may delay revenue recognition and impact rebates or chargebacks.
• Legislative and regulatory changes in the healthcare system, such as the 'One Big Beautiful Bill Act' (OBBBA), could reduce the number of insured Americans, potentially decreasing demand for products.
• International trade policies, including tariffs, sanctions, and trade barriers, may adversely affect business, financial condition, and results of operations due to reliance on a global supply chain and foreign manufacturers.
• Increased production costs and reduced profitability due to tariffs, with limited ability to adjust pricing in formulary-based markets.
• Changes to promotion and advertising rules and regulations, such as crackdowns on deceptive direct-to-consumer (DTC) pharmaceutical advertising, could indirectly impact product demand.
• Uncertainty regarding the recoverability of UK R&D tax credits for the accounting period to December 2023, which is subject to agreement by the UK tax authority and currently untested in courts, potentially leading to a material reduction in tax credit value.
• The company expects to incur significant expenses and operating losses for the foreseeable future and will need significant additional capital to fund operations.
• Inability to raise additional capital on favorable terms or at all, or failure to enter into partnership agreements, could lead to curtailment of development efforts and planned operations.

Future Outlook

The company expects its existing cash, cash equivalents, and marketable securities to fund operations for at least twelve months from November 12, 2025. Commercial launch of AUCATZYL in the United Kingdom is anticipated pending appropriate reimbursement levels from NICE. However, no EU sales of AUCATZYL are anticipated in 2025 and 2026, with the Germany launch on hold. The first patient in the Phase 2 LUMINA trial for obe-cel in lupus nephritis is expected to be dosed prior to December 31, 2025. Research and development expenses are projected to increase substantially over the next few years due to increased personnel costs, additional clinical trials, and regulatory filings. Selling, general and administrative expenses are also expected to rise to support commercial operations, particularly for AUCATZYL sales and marketing. The company will no longer qualify for UK SME R&D tax relief in the accounting period ending December 31, 2025, but may claim under the merged RDEC regime.

Management Comments

• "We believe our programmed T cell therapies have the potential to be best-in-class and to offer patients substantial benefits over the existing standard of care, including the potential for cure in some patients."
• "Based on our current clinical development and commercialization plans, we believe our existing cash, cash equivalents and marketable securities will be sufficient to fund our current and planned operating expenses and capital expenditure requirements through at least the next twelve months from the date of issuance of our unaudited condensed consolidated financial statements included in this Quarterly Report."
• "Management does not know whether additional financing will be on terms favorable or acceptable to us when needed, if at all. If adequate additional funds are not available when required, or if we are unsuccessful in entering into partnership agreements for further development of our product candidates, management may need to curtail its development efforts and planned operations."

Industry Context

The company operates in the highly competitive and rapidly evolving biopharmaceutical industry, focusing on CAR T-cell therapies for oncology and expanding into autoimmune diseases. The regulatory landscape, particularly concerning drug pricing and reimbursement in the US and EU, significantly influences commercialization strategies and profitability. Global supply chain dependencies and international trade policies, including tariffs, present ongoing risks to manufacturing costs and timelines. Strategic collaborations, such as those with BioNTech and Moderna, are common in the biotech sector to leverage expertise, share development costs, and expand pipeline reach. The company's expansion into autoimmune diseases with CAR T-cell therapy reflects an emerging trend in the field, broadening the application of these advanced therapeutic modalities beyond traditional cancer treatments.

Comparison to Industry Standards

• The company's AUCATZYL is being evaluated against TECARTUS (brexucabtagene autoleucel) for relapsed acute lymphoblastic leukemia (r/r ALL) in real-world outcomes data, indicating a direct comparison with an established CAR T-cell therapy competitor.
• The voluntary withdrawal of obe-cel from EU orphan drug designation due to difficulties in achieving a commercially viable price highlights the challenging reimbursement environment in Europe, a common hurdle for innovative, high-cost therapies compared to global benchmarks.
• The expansion of obe-cel into autoimmune diseases like lupus nephritis and progressive multiple sclerosis positions the company among innovative biotech firms exploring novel applications for cell therapies, though specific comparable projects or companies for these indications are not detailed in the filing.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material legal proceedings and is not aware of any pending or threatened legal proceeding that could have an adverse effect on its business, operating results, or financial condition.
• There is an uncertainty regarding the company's claim for SME Research and Development (R&D) tax credit for the accounting period to December 2023, as the relevant tax legislation is currently untested in the United Kingdom courts and in conflict with the tax authority's non-statutory guidance. If the claim is unsuccessful, it would result in a material reduction in the value of the tax credit obtained (18.6% as opposed to 26.97% net benefit).

Related Party Transactions

• **Blackstone Agreements:** Blackstone became a related party in November 2021, owning more than 10% of the company's outstanding voting securities and having the right to nominate a director. As of September 30, 2025, Blackstone holds more than 5% of the company's outstanding voting securities. The carrying amount of the Blackstone Collaboration Agreement Liability was $219.5 million as of September 30, 2025. For the nine months ended September 30, 2025, aggregated cumulative non-cash interest expense and cumulative catch-up adjustment amounted to $9.5 million, and revenue share payments were $1.6 million.
• **BioNTech Agreements:** BioNTech became a related party in February 2024, owning more than 10% of the company's outstanding voting securities and having the right to nominate a director (not yet exercised). The carrying amount of the BioNTech Liability was $39.9 million as of September 30, 2025. For the nine months ended September 30, 2025, aggregated cumulative interest expense and cumulative catch-up adjustment amounted to $4.3 million, and revenue share payments were $0.9 million.

Stakeholder Impact

• **Shareholders:** Face potential dilution from future equity offerings and continued operating losses, which may impact share value. Positive clinical trial data and commercialization efforts could drive value, but uncertainty around UK R&D tax credits could affect financial results.
• **Employees:** Benefit from increased headcount in commercial, manufacturing, clinical, medical, and development roles. New share purchase and inducement plans offer equity incentives, while some employees have been reallocated to commercial manufacturing activities.
• **Customers (Authorized Treatment Centers, Patients):** Experience increased access to AUCATZYL in the US, with 60 activated centers and over 90% medical coverage. Patient assistance programs for travel, lodging, meals, and co-pays are in place. However, potential delays in UK and EU market access for AUCATZYL may affect patient availability in those regions.
• **Suppliers/Partners:** Continue to engage in ongoing collaborations with entities like BioNTech, Moderna, UCL, Cardinal Health, and Miltenyi Biotec. The company has increased purchase obligations for capital equipment and reagents/consumables. Risks from international trade policies (e.g., tariffs) could impact the supply chain.
• **Creditors (Blackstone, BioNTech):** Receive revenue share payments and interest on liabilities. Future milestone payments are contingent on regulatory and commercial achievements of the company's products.

Next Steps

• Engage with the National Institute for Health and Care Excellence (NICE) to obtain a recommendation for reimbursement of AUCATZYL by the National Health Service (NHS) for UK commercial launch.
• Evaluate potential pricing and feasibility of market entry opportunities in certain EU countries for AUCATZYL.
• Present data from the Real-World Outcomes Collaborative for CAR T in Adult ALL database at the American Society of Hematology Annual Meeting.
• Present data from the ongoing Phase Ib/II CATULUS study for obe-cel in pediatric r/r B-ALL or B-cell Non-Hodgkin Lymphoma (NHL) at the American Society of Hematology Annual Meeting (ASH) on December 7, 2025.
• Present additional findings from the ongoing CARLYSLE study for obe-cel in severe refractory systemic lupus erythematosus (srSLE) at ASH 2025 in December 2025.
• Dose the first patient in the Phase 2 LUMINA trial for obe-cel in lupus nephritis prior to December 31, 2025.
• Continue initial clinical development of obe-cel in progressive multiple sclerosis (MS) with the Phase 1 BOBCAT trial.
• Continue translational programs with University College London (UCL) to fuel the early-stage pipeline.
• Increase personnel costs, initiate and conduct additional clinical trials, and prepare regulatory filings related to product candidates.
• Expand sales, marketing, and distribution infrastructure in connection with commercializing AUCATZYL and other product candidates.
• Expand infrastructure and facilities to accommodate the growing employee base.
• Maintain, expand, and protect the intellectual property portfolio.

Key Dates

Recommendation

While Autolus has achieved a significant milestone with its first product revenue from AUCATZYL and is advancing multiple promising clinical programs, the company continues to incur substantial operating losses and has a high cash burn rate, necessitating future capital raises. The commercialization efforts in Europe face delays and challenges, as evidenced by the on-hold Germany launch and the withdrawal of EU orphan drug status for obe-cel. The positive clinical updates are encouraging, but the financial position and market access hurdles suggest a 'hold' recommendation. Investors should monitor the pace of AUCATZYL's commercial ramp-up, progress in autoimmune disease trials, and the company's ability to secure additional financing on favorable terms. The stock carries significant risk due to its early commercial stage and ongoing need for capital, but also has substantial upside potential if commercialization accelerates and pipeline assets succeed.

Keywords

CAR T-cell therapy, AUCATZYL, Obe-cel, Acute Lymphoblastic Leukemia, Lupus Nephritis, Multiple Sclerosis, Biopharmaceutical, Oncology, Immunotherapy, SEC Filing, 10-Q, Financial Results, Clinical Trials, Regulatory Approval, Orphan Drug, Biotech